Abstract
Free full text
The Pathophysiology of COVID-19 and SARS-CoV-2 Infection
Covid-19 infection and mortality: a physiologist’s perspective enlightening clinical features and plausible interventional strategies
to the editor: Coronavirus 2019 (also known as SARS-CoV-2, severe acute respiratory syndrome coronavirus 2) binds to angiotensin-converting enzyme 2 receptors (ACE2) in host cells, as reported for its recent preceding epidemic-causing viral family member, SARS-CoV-1, responsible for the 2003–2004 outbreak in southeastern China (10). ACE2 is abundant in the lungs, heart, blood vessels, testis, brain, and intestine (7, 12), and is responsible for the production of angiotensin 1–7, which exerts vasodilatory, natriuretic/diuretic, anti-inflammatory, and antifibrotic effects via the Mas receptor (7, 19). In the lung, the organ most vulnerable to SARS-CoV-2 infection in the ongoing current pandemic, ACE2 is localized to type II (AT2), and to a lesser extent to type I (AT1), alveolar cells (19). Remarkably, AT2 express many genes that are profoundly involved in the reproduction and transmission of the virus (16). The kidney and testis, two additional organs susceptible to SARS-CoV-2, also express high immunoreactivity to ACE2 (7, 12), which, therefore, can be reasonably hypothesized as a candidate for possible involvement in the clinical manifestations of SARS-CoV-2, which also encompass acute kidney injury and impaired fertility (2, 17, 18) (Fig. 1). Furthermore, preliminary available data from infected patients illustrate that patients treated with angiotensin-II inhibitors (ACE-I)/angiotensin receptor blockers (ARBs), or nonsteroidal anti-inflammatory drugs (NSAIDs) exhibit severe symptoms with a higher mortality rate, as compared with nonuser counterparts (2, 17, 18). Of notable relevance is the demonstration that ACE-I, ARBS, and even mineralocorticoid receptor (MR) blockers remarkably augment the expression of ACE-2 both in diabetic patients (9, 17) and in animals with experimental heart failure (8). Similarly, NSAIDs nonselectively block cyclooxygenase (COX)-1 and COX-2, both enzymes being abundant in kidney tissue and well established for the role in beneficial vasodilatory and natriuretic responses, as is the case with ACE2. Thus, inhibition of COX1/2 by NSAIDs or blockade of RAAS by ACE-I or ARBs, along with concomitant elimination of ACE2 by SARS-CoV-2, may underlie the exaggerated vulnerability of hypertensive, diabetic, and cardiovascular disease subjects (2, 17, 18). Therefore, it is appealing to propose and test the implementable hypothesis that activation of Mas receptor by selective compound, such as AVE0091, or the administration of ACE2 blockers, such as targeted antibodies or chemical blockers (MLN-4760), will attenuate SARS-CoV-2 associated morbidity/mortality by preventing viral entry into ACE2-expressing cells (see Fig. 1).
Furin is an additional potential pathway that could be targeted to minimize the infectious and lethal capability of SARS-CoV-2. Furin, also termed paired basic amino acid cleaving enzyme (PACE), has a substrate specificity for the consensus amino acid sequence Arg-X-Lys/Arg-Arg at the cleavage site (4). Besides its key role in the regulation of blood clotting, growth signaling, and tumor progression (13), furin is also involved in the pathogenesis of several viral infections, including HIV and other coronaviruses, where it cleaves viral enveloping proteins, permeating viral functionality (3, 13). The action of furin on the SARS-CoV-2 spike envelope trimeric transmembrane glycoprotein (S) has already been studied in depth (1, 15). This S-glycoprotein, essential for the entry of the virus into the cell, contains two functional domains: an ACE2 binding domain (also called receptor binding domain, RBD) and a second domain (S2) essential for fusion of the viral and cell membranes (10, 16, 19). Furin activity exposes the binding and fusion domains, essential steps for the entry of the virus into the cell (15) (see Fig. 1). Since the S-glycoprotein of all coronaviruses contains a similar furin cleavage site, it is plausible that the activity of this enzyme is essential for the zoonotic transmission of many coronaviruses, including Covid-19 enveloped by a Middle East Respiratory Syndrome (MERS)-CoV and SARS-CoV S-glycoprotein containing a furin cleavage site (1, 15). Furin conceivably exerts its action intracellularly, as well as extracellularly, as it presents also as a circulating enzyme (5). Notably, heart failure specifically is associated with cardiac furin upregulation, perhaps explaining the vulnerability of such patients to Covid-19 infection (6). Moreover, furin is detected in T cells which are activated during infections and circulate through the body (11). This may form a feed-forward loop of furin-facilitated coronavirus replication that may be responsible for hypersensitive immunological response (cytokine storm) in some patients, leading to fulminant myocarditis, ravaged lung tissue, and lethal multiorgan failure. In these perspectives, likely, targeting furin might be an option for the prevention or treatment of SARS-COV-2 infection. Available approaches are using furin inhibitor I, furin convertase inhibitor (chloromethylketone), or peptidyl-chloromethyl ketones, already studied for HIV infection (14).
To conclude, cleavage of the S-glycoprotein by furin and its binding to ACE2-expressing cells in the lung, kidney, heart, intestine, and testis are key steps in the zoonotic SARS-CoV-2 transmission. Upregulation of ACE2 and furin in cardiovascular and metabolic disease states, especially in the presence of ACE-I/ARBS/MR blockers or NSAIDs, may sensitize these patients to the deleterious impact of SARS-CoV-2. Furthermore, it is appealing to assume that inhibition of furin, essential for viral intracellular translocation, or blocking the viral anchoring capability of ACE2 might be potential treatment options in combating this new formidable threat to the health and well-being of the human civilization.
GRANTS
Z.A.A. acknowledges research support from the Israel Science Foundation (No. 544/18). K.S. acknowledges research support from the Israel Science Foundation (Grant 182115) and from the Kaylie Family Foundation.
AUTHOR CONTRIBUTIONS
S.K. prepared figure; Z.A.A. drafted manuscript; Z.A.A., K.S., S.N.H., and Z.A. edited and revised manuscript; Z.A.A., K.S., S.N.H., S.K., and Z.A. approved final version of manuscript.
REFERENCES
Articles from American Journal of Physiology - Lung Cellular and Molecular Physiology are provided here courtesy of American Physiological Society
Full text links
Read article at publisher's site: https://doi.org/10.1152/ajplung.00097.2020
Read article for free, from open access legal sources, via Unpaywall: https://europepmc.org/articles/pmc7200872
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1152/ajplung.00097.2020
Article citations
Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.
Int J Mol Sci, 24(9):8454, 08 May 2023
Cited by: 1 article | PMID: 37176159 | PMCID: PMC10179460
Regulation of Epithelial Sodium Transport by SARS-CoV-2 Is Closely Related with Fibrinolytic System-Associated Proteins.
Biomolecules, 13(4):578, 23 Mar 2023
Cited by: 0 articles | PMID: 37189326 | PMCID: PMC10135759
Review Free full text in Europe PMC
Respiratory issues in patients with multiple sclerosis as a risk factor during SARS-CoV-2 infection: a potential role for exercise.
Mol Cell Biochem, 478(7):1533-1559, 21 Nov 2022
Cited by: 0 articles | PMID: 36411399 | PMCID: PMC9684932
Review Free full text in Europe PMC
Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy.
Cancers (Basel), 14(17):4074, 23 Aug 2022
Cited by: 2 articles | PMID: 36077610 | PMCID: PMC9454734
Nutraceutical prospects of Houttuynia cordata against the infectious viruses.
Food Biosci, 50:101977, 30 Aug 2022
Cited by: 2 articles | PMID: 36059903 | PMCID: PMC9423882
Go to all (46) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Coronavirus disease 2019 and the cardiovascular system: Impacts and implications.
Indian Heart J, 72(1):1-6, 01 Jan 2020
Cited by: 11 articles | PMID: 32423554 | PMCID: PMC7195102
[Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Pneumologie, 74(9):611-614, 11 Sep 2020
Cited by: 0 articles | PMID: 32916743
[Angiotensin II suppression in SARS-CoV-2 infection: a therapeutic approach].
Nefrologia (Engl Ed), 40(3):213-216, 30 Apr 2020
Cited by: 6 articles | PMID: 32456945 | PMCID: PMC7190491
The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.
Arq Bras Cardiol, 114(5):817-822, 01 Jun 2020
Cited by: 12 articles | PMID: 32491073 | PMCID: PMC8386999
Review Free full text in Europe PMC
COVID-19 and Cardiovascular Disease.
Circulation, 141(20):1648-1655, 21 Mar 2020
Cited by: 968 articles | PMID: 32200663
Review